Back Investor

Investor Webinar | Drug Development Programs and Overview

As part of this Investor Webinar, Emyria Managing Director, Dr Michael Winlo, explains Emyria’s novel cannabinoid and MDMA drug development programs and the importance of registration with the TGA and FDA.

This includes an overview of the Company’s recent ASX announcements, “Emyria Executes Pure CBD Agreement with Altasciences” and “Emyria to Develop Novel Psychedelics Pipeline with UWA as well as a discussion of the imminent independent report to inform the possible re-scheduling of MDMA and psilocybin with the TGA.

Watch the 40-minute webinar here.

Investor Webinar ‘Drug Development Programs and Overview”- 24 August 2021 from JMM on Vimeo.

Have Questions?

If you have any question, please feel free to get in touch with us.

Call 1300 436 363Contact